Business
BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical
About this update from Beyondspring, Inc.
[{"type":"text","content":"NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been enrolled in BeyondSpring’s Phase 2 investigator-initiated trial with lead asset, Plinabulin, in combination with Merck’s anti-PD-1 therapy Keytruda® (pembrolizumab) and Docetaxel for previously treated patients with metastatic non-small cell lung cancer (NSCLC) and progressive disease after immunotherapy (anti-PD-1 / PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. Most patients experience disease progression after immune checkpoint inhibitor-based (ICI) treatment regimens. BeyondSpring’s triple-combination therapy has the potential to improve ICI resistance and provide a new treatment option for metastatic NSCLC patients previously treated with an immunotherapy. The study1 is actively recruiting at Peking Union Medical College Hospital in Beijing, China, with Dr. Mengzhao Wang, Chief of the Department of Respiratory and Critical Care Medicine, as principal investigator. Patients will receive the following doses during each three-week cycle (via IV infusions)2: Plinabulin at 30 mg / m2 on Days 1 and 8Keytruda at 200 mg on Day 1Docetaxel at 75 mg / m² on Day 1 “While PD-1 / PD-L1 inhibitors have significantly advanced cancer treatment, patients still experience disease progression even after receiving these therapies,” said Dr. Wang. “This triple combination study is bringing us one step closer to helping with this unmet medical need. Plinabulin’s unique, immune-enhancing mechanism of action has a proven anti-cancer benefit that we believe will synergize with Docetaxel and Keytruda and re-sensitize patients who progressed after immunotherapy. In fact, Plinabulin has shown a 40 percent response rate in its immune-oncology combination in small-cell lung cancer patients who experienced disease progression after immunotherapy3. I look forward to evaluating this treatment further in the clinic to ensure that cancer patients all over the world have access to the most advanced, cutting-edge therapies.” “As 25 to 30 percent of patients suffering from metastatic NSCLC have a life expectancy of under three months4, it is our mission to find better treatme...